(TNX-1500) in Kidney Transplant Recipients

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Ayman Al Jurdi, MD
Study ID
NCT07204080
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Immunosuppression
  • Immunosuppression After Kidney Transplantation
  • Kidney Transplant
  • Kidney Transplant Failure and Rejection

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • TNX-1500 — DRUG
    This is an open-label, single-center, single-arm study to assess the safety and efficacy of TNX-1500, an Fc-modified anti-DF154 mAb in five adult kidney transplant recipients.
  • Kidney Transplant — PROCEDURE
    Kidney Transplant

Study Details

The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.

Key Dates

Start date
Jul 1, 2026
Status verified
Feb 2026
Primary completion
Sep 1, 2028
Completion
Jun 30, 2029

Study Design

Enrollment
5 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Kidney Transplant Recipient

Primary Outcome Measure

Number of Adverse Events in each subject [ Time Frame: 12 Months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Ayman Al Jurdi, MD (PRINCIPAL_INVESTIGATOR)
Massachusetts General HospitalBostonMassachusetts02114
Ayman Al Jurdi
[email protected]
617-726-2000

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital· Boston, MA

Related Studies